As a future perspective, the quantification of functional splice variants of NER components, e.g. XPG or XPF, in certain high-risk cancer populations (even for different cancer types and tumor entities) could be applied to investigate this variants as prognostic marker for beneficial or negative influences of cancer development, disease outcome, therapeutic responses, and side effects. This evidence concerns the gene ERCC5 and neoplasm.